虽然临床前研究一直暗示FGFR信号传导在乳腺癌(BC)进展中,临床证据不能支持这些发现.FGFR的临床意义可能应该在基质的背景下进行分析,激活或抑制其功能。本综述旨在通过总结有关选定的癌症相关成纤维细胞(CAFs)相关因子的预后和/或预测价值的现有数据来提供这样的背景。这可能直接或间接影响FGFR信令。PubMed(https://pubmed.ncbi.nlm.nih.gov/)和Medline(https://www.nlm.nih.gov/medline/medline_home.html)数据库中搜索了与以下因素的预后和/或预测意义相关的相关文献:CAFs表型标记(αSMA,S100A4/FSP‑1,PDGFR,PDPN和FAP),CAFs衍生的同源FGFR配体(FGF2,FGF5和FGF17)或CAFs旁分泌活性的诱导剂(TGF-β1,HDGF,PDGF,CXCL8,CCL5,CCL2,IL‑6,HH和EGF)均在肿瘤中表达并在血液中循环。总共选择了68篇文章并进行了全面分析。这些发现一致地确定了αSMA的上调,S100A4/FSP‑1,PDGFR,PDPN,HDGF,PDGF,CXCL8,CCL5,CCL2,IL-6,HH和EGF作为BC的不良预后标志物,而对其余标志物的预后价值的评估在研究之间有所不同。数据证实了CAFs特异性特征与BC预后的关联,提示可能需要对基质进行定量和定性分析以评估真实FGFR的临床价值.
While preclinical studies consistently implicate
FGFR‑signalling in breast cancer (BC) progression, clinical evidence fails to support these findings. It may be that the clinical significance of
FGFR ought to be analysed in the context of the stroma, activating or repressing its function. The present review aimed to provide such a context by summarizing the existing data on the prognostic and/or predictive value of selected cancer‑associated fibroblasts (CAFs)‑related factors, that either directly or indirectly may affect
FGFR‑signalling. PubMed (https://pubmed.ncbi.nlm.nih.gov/) and Medline (https://www.nlm.nih.gov/medline/medline_home.html) databases were searched for the relevant literature related to the prognostic and/or predictive significance of: CAFs phenotypic markers (αSMA, S100A4/FSP‑1, PDGFR, PDPN and FAP), CAFs‑derived cognate
FGFR ligands (FGF2, FGF5 and FGF17) or inducers of CAFs\' paracrine activity (TGF‑β1, HDGF, PDGF, CXCL8, CCL5, CCL2, IL‑6, HH and EGF) both expressed in the tumour and circulating in the blood. A total of 68 articles were selected and thoroughly analysed. The findings consistently identified upregulation of αSMA, S100A4/FSP‑1, PDGFR, PDPN, HDGF, PDGF, CXCL8, CCL5, CCL2, IL‑6, HH and EGF as poor prognostic markers in BC, while evaluation of the prognostic value of the remaining markers varied between the studies. The data confirm an association of CAFs‑specific features with BC prognosis, suggesting that both quantitative and qualitative profiling of the stroma might be required for an assessment of the true
FGFR\'s clinical value.